Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Announces First Participant Dosed in Phase 1 Trial of DNTH103, a Selective Inhibitor of the Classical Complement Pathway","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dianthus Therapeutics Announces $230 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Gets FDA Clearance for Phase 2 Trial of DNTH103 in MMN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Dianthus Therapeutics

    Menu

    Dianthus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dianthus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dianthus Therapeutics Gets FDA Clearance for Phase 2 Trial of DNTH103 in MMN

              Details:

              DNTH103 is a potent monoclonal antibody engineered to selectively inhibitis only the active form of the C1s protein. It is being evaluated for the treatment of Multifocal Motor Neuropathy.

              Lead Product(s): DNTH103

              Therapeutic Area: Neurology Product Name: DNTH103

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dianthus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

              Details:

              DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. It is being evaluated for the treatment of generalized myasthenia gravis.

              Lead Product(s): DNTH103

              Therapeutic Area: Immunology Product Name: DNTH103

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dianthus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dianthus Therapeutics Announces $230 Million Private Placement

              Details:

              The net proceeds will be used for the clinical development of DNTH103. It is a selective inhibitor of the active C1s protein for the treatment of neuromuscular & autoimmune disorders.

              Lead Product(s): DNTH103

              Therapeutic Area: Immunology Product Name: DNTH103

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $230.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement January 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dianthus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

              Details:

              The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103, an investigational long-acting classical complement pathway inhibitor, currently in a Phase 1 trial to treat people with severe autoimmune diseases.

              Lead Product(s): DNTH103

              Therapeutic Area: Immunology Product Name: DNTH103

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Magenta Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dianthus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

              Details:

              The net financing will be used to fund DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications.

              Lead Product(s): DNTH103

              Therapeutic Area: Immunology Product Name: DNTH103

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Fidelity Management & Research

              Deal Size: $70.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dianthus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dianthus Therapeutics Announces First Participant Dosed in Phase 1 Trial of DNTH103, a Selective Inhibitor of the Classical Complement Pathway

              Details:

              DNTH103 is a next-generation monoclonal antibody that selectively targets only the active form of the C1s protein in the classical complement pathway. DNTH103 is designed as an infrequent and convenient subcutaneous injection.

              Lead Product(s): DNTH103

              Therapeutic Area: Immunology Product Name: DNTH103

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY